Could proposed legislation undercut the promise of targeted therapies?
Jim Hollingshead, Deloitte Consulting LLP
Advertisement
Articles by Jim Hollingshead, Deloitte Consulting LLP
Advertisement
Latest Updated Articles
- The stakes are high in the debate over follow-on biologics
Published: May 3rd 2009 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Mark Cuban Disrupts Drug Pricing, AstraZeneca Expands US Manufacturing, and BMS Bets Big on RNA Therapeutics
2
LogiPharma USA 2025: Challenges Currently Impacting the Temperature-Controlled Space
3
